OBJECTIVE: Postmenopausal changes in the hormonal milieu in women with or without hormone therapy are hypothesized to be the pathway for a number of menopause-associated modifications in physiology and disease risk. Physical activity may modify these changes in women's hormone profiles. The crucial yet complex relationship between physical activity and physiologic and pharmacologic sex hormone levels in postmenopausal women has not been investigated sufficiently. METHODS: Using structured recall, physical activity was assessed longitudinally during a period of 2 years in 194 postmenopausal women (90randomized to 1 mg 17β-estradiol treatment daily and 104 randomized to placebo) in the Estrogen in the Prevention of Atherosclerosis Trial. The levels of physical activity were correlated with the serum sex hormone and the serum hormone-binding globulin levels in each treatment group. RESULTS: Among the placebo-treated women, total energy expenditure was positively associated with sex hormone-binding globulin (SHBG; P < 0.001) and inversely associated with testosterones (total, bioavailable, or free) and androstenedione (P < 0.001 for all), as well as with estradiol (P = 0.02). In estradiol-treated women, estradiol levels were inversely associated with total energy expenditure (P = 0.002) and weekly hours spent in moderate or more vigorous physical activity (P = 0.001). CONCLUSIONS: Physical activity is associated with lower serum levels of estradiol in both hormone therapy-treated and untreated women. In placebo-treated women only, physical activity is associated with reduced androgen levels and elevated SHBG levels.
RCT Entities:
OBJECTIVE: Postmenopausal changes in the hormonal milieu in women with or without hormone therapy are hypothesized to be the pathway for a number of menopause-associated modifications in physiology and disease risk. Physical activity may modify these changes in women's hormone profiles. The crucial yet complex relationship between physical activity and physiologic and pharmacologic sex hormone levels in postmenopausal women has not been investigated sufficiently. METHODS: Using structured recall, physical activity was assessed longitudinally during a period of 2 years in 194 postmenopausal women (90 randomized to 1 mg 17β-estradiol treatment daily and 104 randomized to placebo) in the Estrogen in the Prevention of Atherosclerosis Trial. The levels of physical activity were correlated with the serum sex hormone and the serum hormone-binding globulin levels in each treatment group. RESULTS: Among the placebo-treated women, total energy expenditure was positively associated with sex hormone-binding globulin (SHBG; P < 0.001) and inversely associated with testosterones (total, bioavailable, or free) and androstenedione (P < 0.001 for all), as well as with estradiol (P = 0.02). In estradiol-treated women, estradiol levels were inversely associated with total energy expenditure (P = 0.002) and weekly hours spent in moderate or more vigorous physical activity (P = 0.001). CONCLUSIONS: Physical activity is associated with lower serum levels of estradiol in both hormone therapy-treated and untreated women. In placebo-treated women only, physical activity is associated with reduced androgen levels and elevated SHBG levels.
Authors: B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon Journal: Med Sci Sports Exerc Date: 2000-09 Impact factor: 5.411
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Karen A Matthews; Sybil L Crawford; Claudia U Chae; Susan A Everson-Rose; Mary Fran Sowers; Barbara Sternfeld; Kim Sutton-Tyrrell Journal: J Am Coll Cardiol Date: 2009-12-15 Impact factor: 24.094
Authors: Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Tricia M Peters; Steven C Moore; Gretchen L Gierach; Nicholas J Wareham; Ulf Ekelund; Albert R Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: BMC Cancer Date: 2009-10-01 Impact factor: 4.430
Authors: Mark A Guinter; Alexander C McLain; Anwar T Merchant; Dale P Sandler; Susan E Steck Journal: Breast Cancer Res Treat Date: 2018-04-12 Impact factor: 4.872
Authors: Christine A Cabelka; Cory W Baumann; Brittany C Collins; Nardina Nash; Gengyun Le; Angus Lindsay; Espen E Spangenburg; Dawn A Lowe Journal: Exp Gerontol Date: 2018-11-08 Impact factor: 4.032
Authors: Hannah Oh; Nazmus Saquib; Heather M Ochs-Balcom; Ruth M Pfeiffer; Phyllis A Richey; Aladdin H Shadyab; Robert A Wild; Lisa Underland; Garnet L Anderson; Xia Xu; Britton Trabert Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-18 Impact factor: 4.090
Authors: Christopher T V Swain; Ann E Drummond; Leonessa Boing; Roger L Milne; Dallas R English; Kristy A Brown; Eline H van Roekel; Suzanne C Dixon-Suen; Michael J Lynch; Melissa M Moore; Tom R Gaunt; Richard M Martin; Sarah J Lewis; Brigid M Lynch Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-20 Impact factor: 4.254
Authors: Hannah Oh; Hannah Arem; Charles E Matthews; Nicolas Wentzensen; Kerryn W Reding; Louise A Brinton; Garnet L Anderson; Sally B Coburn; Jane A Cauley; Chu Chen; Deborah Goodman; Ruth M Pfeiffer; Roni T Falk; Xia Xu; Britton Trabert Journal: Br J Cancer Date: 2017-08-17 Impact factor: 7.640